SAFER MEDICINE READING
Reading a medicine label in larger print: mg, tablets, splitting, switching and combinations
Six practical questions make a small-print label easier to discuss: identify the exact product, understand what a strength means, check manipulation, prevent duplication and bring a complete medicine list to a pharmacist or prescriber.
Write down five product identifiers
Do not rely on a brand name alone when several medicines are involved. Keep the brand or non-proprietary name, the declared active ingredient and strength per unit, dosage form, route, intended market and label version together. ‘mg’ normally describes the declared amount of active ingredient in one dosage unit; it is not an instruction for how many units a person should take. The prescribed amount depends on the labelled use, age, kidney and liver function, other medicines and the exact formulation. A strength such as 250 mg or 500 mg cannot safely be converted into a personal tablet or capsule count on its own.
Read micrograms (mcg or μg) and milligrams (mg) with their units
Some packs state mcg, μg or micrograms; others state mg or milligrams. They are not the same unit, and a number without its unit is not a complete product identity. Copy the name, dosage form, number and unit exactly into a medicine list, then compare them with the actual prescription label and current product information. Do not use a webpage to turn micrograms or milligrams into a personal tablet count, or to self-switch to a product, strength or form because the numbers look similar.
Splitting is not simple arithmetic
A half-tablet may be appropriate only when the exact product label supports it and a pharmacist or prescriber has confirmed it. FDA notes that if a label does not include splitting information, it has not evaluated whether the halves have equal weight or drug content, or work the same way as the whole tablet. Most sustained-, controlled- or timed-release medicines are not intended to be split. A new strength, manufacturer, coating or formulation needs a fresh check even when a previous pack could be split.
Do not self-combine, alternate or switch medicines in the same class
When two medicines appear to have a similar purpose, first check whether they duplicate an ingredient, therapeutic class, dosage form or strength. Do not independently take them together, alternate them or substitute one for another until the prescriber or pharmacist has checked the full situation. Atorvastatin and rosuvastatin, for example, are both statins. A decision to switch, pause, combine or adjust one depends on prior effects, disease risk, other medicines, test results and the applicable label—not a product name or an every-other-day rule.
Genes can be relevant without making whole-genome testing a default
Medicine choice can also depend on prior reactions, kidney and liver function, coexisting conditions, pregnancy or breastfeeding, the complete medicine list and the exact product label. Pharmacogenomic results can help professionals interpret exposure or adverse-effect risk in defined situations. The CPIC statin guideline explains how to use available SLCO1B1, ABCG2 and CYP2C9 results; it does not decide who should receive broad genetic testing. A genetic result should not be used to self-select, stop or switch treatment.
When genetic testing is worth asking about
Do not read ‘pharmacogenetic testing’ as a whole-genome screen that everyone needs. FDA separates the evidence: some gene-drug associations can support specific therapeutic-management recommendations, while others indicate a possible effect on safety, response or drug exposure; inclusion in the table does not automatically mean testing is required before every prescription. The useful question is whether the exact medicine, current label in the intended market, prior reactions and complete medicine list raise a defined issue for a clinician or pharmacist to consider. A professional should decide whether a test is needed, when it is useful and how a result is interpreted; a result never replaces checking kidney and liver function, interactions, disease status and the current label.
Include OTC products, supplements and food in a combination check
Interactions are not only between two prescriptions. FDA distinguishes medicine-medicine, medicine-food or beverage, and medicine-condition interactions. Cold remedies, pain relievers, vitamins, minerals, herbal products and alcohol can all change what needs review. Bring a complete list: name, active ingredient, strength, dosage form, actual timing, start date and any symptoms. Do not omit a product simply because it is non-prescription.
Six questions to bring to a pharmacist or prescriber
What active ingredient, dosage form and per-unit strength does this pack contain? What does my own prescription label instruct, rather than what number of milligrams is printed on the box? May this exact product be split, crushed, opened or taken with food? What needs checking against my medicines, OTC products, supplements, herbs and usual foods? How should a change of brand, strength, formulation or class be made? Which symptoms mean I should contact the care team promptly or seek urgent help?
What this site can and cannot do
OriginDrug enlarges the dosage form, route, source label, document date and market boundary of each record. It can help a reader identify the right question and the right source document. It does not generate a personal dose, combination plan, switch plan or genetic-testing decision. Prescription changes, children or older adults, pregnancy, kidney or liver disease, multiple medicines, allergy history or significant new symptoms call for direct review by a clinician or pharmacist.
PRIMARY REFERENCE
Source evidence
Each entry identifies its market, document type, access mode and most recent review date. Public access does not make a document applicable to every market or person. Read the review method.
- FDA: Tablet Splitting ↗reviewed 2026-08-20
- FDA: Drug Interactions: What You Should Know ↗reviewed 2026-08-20
- FDA: Prescribing Information Resources ↗reviewed 2026-08-20
- FDA: Administration instructions for modified-release dosage forms ↗reviewed 2026-08-20
- FDA: Table of Pharmacogenetic Associations ↗reviewed 2026-08-20
- CPIC: Statin pharmacogenomic guideline (2022) ↗reviewed 2026-08-20